Literature DB >> 24939670

Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study.

H J Scheffer1, K Nielsen, A A J M van Tilborg, J M Vieveen, R A Bouwman, G Kazemier, H W M Niessen, S Meijer, C van Kuijk, M P van den Tol, M R Meijerink.   

Abstract

OBJECTIVES: Irreversible electroporation (IRE) is a new ablation technique that relies on high-voltage electrical pulses. This clinical study evaluates the pathological response of colorectal liver metastases (CRLM) treated with IRE and the clinical safety and feasibility.
METHODS: Ten patients with resectable CRLM were included. During laparotomy, the metastases were treated with IRE and resected 60 min later. Safety and feasibility were assessed based on adverse events, laboratory values, technical success and intra-operative ultrasound findings. Tissue response was assessed using triphenyl tetrazolium chloride (TTC) vitality staining and (immuno)histochemical stainings (HE, complement-3d and caspase-3).
RESULTS: Ten lesions with a mean diameter of 2.4 cm were successfully electroporated and resected, on average, 84 min later (range 51-153 min). One minor transient cardiac arrhythmia occurred during IRE. Ultrasound showed a sharply demarcated hypoechoic ablation zone around the tumour. TTC showed avitality of all lesions, covering the complete tumour in 8/10 lesions. Although immunohistochemistry proved heterogeneous and difficult to interpret within the tumours, it confirmed irreversible cell damage in the tumour-free margin of all specimens.
CONCLUSIONS: This ablate-and-resect study demonstrated avitality caused by IRE of CRLM in humans. Further characterisation of tissue- and tumour-specific electrical properties is warranted to improve ablation protocols for maximised tissue ablation. KEY POINTS: • Irreversible electroporation induces cell death in colorectal liver metastases within 1 h. • The ablation zone shows a sharp demarcation between avital and vital tissue. • Apoptosis is involved in cell death of colorectal liver metastases after IRE. • Effects of IRE can be monitored real-time using intraoperative ultrasound. • Local electrical heterogeneities of tumour tissue may require tumour-specific ablation protocols.

Entities:  

Mesh:

Year:  2014        PMID: 24939670     DOI: 10.1007/s00330-014-3259-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

Review 2.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome.

Authors:  Antoni Ivorra; Bassim Al-Sakere; Boris Rubinsky; Lluis M Mir
Journal:  Phys Med Biol       Date:  2009-09-17       Impact factor: 3.609

Review 4.  The membrane attack complex of complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Ablation of perivascular hepatic malignant tumors with irreversible electroporation.

Authors:  T Peter Kingham; Ami M Karkar; Michael I D'Angelica; Peter J Allen; Ronald P Dematteo; George I Getrajdman; Constantinos T Sofocleous; Stephen B Solomon; William R Jarnagin; Yuman Fong
Journal:  J Am Coll Surg       Date:  2012-06-16       Impact factor: 6.113

6.  Irreversible electroporation: a new challenge in "out of operating theater" anesthesia.

Authors:  Christine Ball; Kenneth R Thomson; Helen Kavnoudias
Journal:  Anesth Analg       Date:  2010-02-08       Impact factor: 5.108

7.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

8.  Irreversible electroporation: a novel image-guided cancer therapy.

Authors:  Edward W Lee; Susan Thai; Stephen T Kee
Journal:  Gut Liver       Date:  2010-09-10       Impact factor: 4.519

9.  Incidence and treatment of local site recurrences following RFA of colorectal liver metastases.

Authors:  Karin Nielsen; Aukje A J M van Tilborg; Martijn R Meijerink; Matessa O Macintosh; Babs M Zonderhuis; Elly S M de Lange; Emile F I Comans; Sybren Meijer; M Petrousjka van den Tol
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

10.  Irreversible electroporation: an in vivo study with dorsal skin fold chamber.

Authors:  Zhenpeng Qin; Jing Jiang; Gary Long; Bruce Lindgren; John C Bischof
Journal:  Ann Biomed Eng       Date:  2012-11-22       Impact factor: 3.934

View more
  26 in total

Review 1.  Irreversible Electroporation.

Authors:  Govindarajan Narayanan
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 2.  Local treatment of oligometastatic disease: current role.

Authors:  Moritz T Winkelmann; Stephan Clasen; Philippe L Pereira; Rüdiger Hoffmann
Journal:  Br J Radiol       Date:  2019-06-06       Impact factor: 3.039

3.  Recurrence patterns following irreversible electroporation for hepatic malignancies.

Authors:  Russell C Langan; Debra A Goldman; Michael I D'Angelica; Ronald P DeMatteo; Peter J Allen; Vinod P Balachandran; William R Jarnagin; T Peter Kingham
Journal:  J Surg Oncol       Date:  2017-05-11       Impact factor: 3.454

4.  MRI-TRUS fusion for electrode positioning during irreversible electroporation for treatment of prostate cancer.

Authors:  Alexander D J Baur; Federico Collettini; Judith Enders; Andreas Maxeiner; Vera Schreiter; Carsten Stephan; Bernhard Gebauer; Bernd Hamm; Thomas Fischer
Journal:  Diagn Interv Radiol       Date:  2017 Jul-Aug       Impact factor: 2.630

5.  In vivo evaluation of bronchial injury of irreversible electroporation in a porcine lung ablation model by using laboratory, pathological, and CT findings.

Authors:  Jun-Hui Sun; Tong-Yin Zhu; Xin-Hua Chen; Chun-Hui Nie; Zhi-Gang Ren; Guan-Hui Zhou; Tan-Yang Zhou; Sheng-Yong Yin; Zhi-Yi Peng; Li-Ming Wu; Xiong-Xin Zhang; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

6.  Real-Time Spatiotemporal Control of High-Intensity Focused Ultrasound Thermal Ablation Using Echo Decorrelation Imaging in ex Vivo Bovine Liver.

Authors:  Mohamed A Abbass; Jakob K Killin; Neeraja Mahalingam; Fong Ming Hooi; Peter G Barthe; T Douglas Mast
Journal:  Ultrasound Med Biol       Date:  2017-10-23       Impact factor: 2.998

7.  Peri-tumoral Metallic Implants Reduce the Efficacy of Irreversible Electroporation for the Ablation of Colorectal Liver Metastases.

Authors:  Francois H Cornelis; Helena Cindrič; Bor Kos; Masashi Fujimori; Elena N Petre; Damijan Miklavčič; Stephen B Solomon; Govindarajan Srimathveeravalli
Journal:  Cardiovasc Intervent Radiol       Date:  2019-08-05       Impact factor: 2.740

Review 8.  Hepatic metastasis from colorectal cancer.

Authors:  Alfred Wei Chieh Kow
Journal:  J Gastrointest Oncol       Date:  2019-12

9.  Echo Decorrelation Imaging of Rabbit Liver and VX2 Tumor during In Vivo Ultrasound Ablation.

Authors:  Tyler R Fosnight; Fong Ming Hooi; Ryan D Keil; Alexander P Ross; Swetha Subramanian; Teckla G Akinyi; Jakob K Killin; Peter G Barthe; Steven M Rudich; Syed A Ahmad; Marepalli B Rao; T Douglas Mast
Journal:  Ultrasound Med Biol       Date:  2016-10-04       Impact factor: 2.998

10.  Electric Ablation with Irreversible Electroporation (IRE) in Vital Hepatic Structures and Follow-up Investigation.

Authors:  Xinhua Chen; Zhigang Ren; Tongyin Zhu; Xiongxin Zhang; Zhiyi Peng; Haiyang Xie; Lin Zhou; Shengyong Yin; Junhui Sun; Shusen Zheng
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.